Transgenic Mice Antibody Discovery Overview

Following the hybridoma technology and antibody library display technology, antibody production by transgenic mouse technology has become a research hotspot. At present, the technology of antibody production by transgenic mice has been relatively mature. At the same time, transgenic mouse technology has witnessed its own value with its strength. There are many antibody drugs prepared based on transgenic mouse technology. However, the transgenic mouse technology platform for fully human antibodies still has high technical barriers and requires a more specialized platform for its production. Based on our rich field experience and advanced platform, Creative Biolabs provides comprehensive transgenic mouse/rat hybridoma technologies and services to support fully human antibody discovery.

Fig 1. Mouse. (Creative Biolabs Authorized)

Transgenic Mice Antibody Discovery

The fully human antibody transgenic mouse technology brings the functionality of transgenic technology to the forefront in the field of antibody drugs. There are already many antibody drugs being developed based on transgenic mouse technology. And these antibody drugs have brought huge profits to these research and development companies. The technology is to humanize the immunoglobulin genome of mice so that human antibody genes are expressed in transgenic mice instead of mouse antibody genes, and by immunizing such transgenic mice, they are able to produce corresponding fully human antibodies against different antigens. Since the in vivo system of recognizing antigens and mobilizing antibodies remains intact in mice, it is easy to recognize human proteins as foreign substances, which makes them more suitable for the development of endogenous targets such as tumors and autoimmune diseases. Also, because antibodies from transgenic animal sources undergo a complete process of somatic mutation and affinity maturation, antibody optimization is accomplished naturally in mice through high-frequency mutation of DNA, which provides a great advantage in terms of antibody affinity and druggability and therefore saves time for late-stage antibody engineering and modification.

However, the establishment of a fully human transgenic mouse platform is a huge undertaking. Since the ability of antibody development depends on the diversity of antibodies produced, the higher the antibody diversity, the higher the probability of producing antibodies with high affinity and drug-forming properties. The basis of antibody diversity depends on the length and completeness of the imported human immunoglobulin gene. In other words, the longer the sequence of the imported human antibody gene and the more complete the gene structure, the greater the diversity of antibodies produced and the closer they are to human antibodies. By combining mouse/rat with existing antibody preparations, it is possible to obtain highly specific, high affinity antibody candidates from these transgenic animals. These are transgenic mouse/rat hybridoma technology, transgenic mouse/rat plasma cell sorting technology, and transgenic phage display library technology.

Single-domain antibodies (sdAbs) have a unique position in the field of antibodies, which have great potential in the field of biochemical research and the development of new diagnostic and therapeutic methods. And current technology has made it possible to obtain sdAbs for the whole human VH region based on transgenic mouse technology. This is an important breakthrough in the development of fully human sdAbs and, at the same time, promotes research in the field of sdAbs.

Creative Biolabs has a wealth of knowledge and experience in transgenic mouse antibody discovery. We would be happy to share with you our knowledge and experience.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: